Gliknik Inc.
Clinical trials sponsored by Gliknik Inc., explained in plain language.
-
New shot aims to boost platelets in bleeding disorder
Disease control Recruiting nowThis early-stage trial tests an injectable drug called GL-2045 in 42 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if GL-2045 can safely raise platelet counts like standard IVIg therapy…
Phase: PHASE1 • Sponsor: Gliknik Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug GL-0719 enters first human trials for rare blood disorder
Disease control Recruiting nowThis early-stage trial tests a new drug called GL-0719 in healthy volunteers and people with cold agglutinin disease, a rare condition where cold temperatures cause the immune system to destroy red blood cells. The study aims to check safety, how the drug moves through the body, …
Phase: PHASE1 • Sponsor: Gliknik Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC